Skip to search formSkip to main contentSkip to account menu

bezlotoxumab

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Clostridium difficile infection (CDI) is a leading nosocomial disease estimated to cause nearly half a million cases in the… 
Highly Cited
2018
Highly Cited
2018
Abstract Background Bezlotoxumab is a human monoclonal antibody against Clostridium difficile toxin B indicated to prevent C… 
2018
2018
Background Clostridium difficile infection (CDI) is the most commonly recognized cause of recurrent diarrhea. Bezlotoxumab… 
Review
2018
Review
2018
Clostridium difficile infection (CDI) is the most common health care-acquired infection associated with high hospital… 
Highly Cited
2017
Highly Cited
2017
Background Clostridium difficile is the most common cause of infectious diarrhea in hospitalized patients. Recurrences are common… 
Review
2017
Review
2017
During the past decade, the incidence and severity of Clostridium difficile infection (CDI) have significantly increased, leading… 
Review
2016
Review
2016
Bezlotoxumab (Zinplava™) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck & Co. In October… 
Highly Cited
2014
Highly Cited
2014
Background: Bezlotoxumab is a neutralizing antibody targeting toxin B of Clostridium difficile. Results: The structure of… 
Highly Cited
2014
Highly Cited
2014
ABSTRACT Clostridium difficile infection (CDI) represents the most prevalent cause of antibiotic-associated gastrointestinal…